Angiotensin-converting enzyme inhibitors and beta-blockers in cardiacasymptomatic patients with duchenne muscular dystrophy

Indian Heart Journal

Volumn 62, Issue 3, 2010, Pages 273-

  Fayssoil, A ^a  

^a RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Ace inhibitors; Beta blockers; Duchenne muscular dystrophy; Dystrophin; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; METOPROLOL SUCCINATE; PERINDOPRIL;

ARTICLE; ASYMPTOMATIC DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ENDOTHELIAL DYSFUNCTION; FUNCTIONAL STATUS; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HUMAN; LENGTH OF STAY; MOLECULAR PATHOLOGY; MORTALITY; MUSCLE ATROPHY; SURVIVAL RATE; SURVIVAL TIME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART DISEASES; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 79952261888     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology. 2003; 99(1):1-19.
2. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct;29(19):2388-442
3. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol. 2002 Dec;34(12):1577-84
4. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO, Towbin JA. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005 Nov 1;112(18):2799-804
5. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
6. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005 Mar 15;45(6):855-7
7. Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol. 2009 Feb;53(1):72-8.
8. Towbin JA. A non-invasive means of detecting preclinical cardiomyopathy in Duchenne muscular dystrophy? J Am Coll Cardiol 2003;42: 317-8.